Iobenguane
- Generic Name
- Iobenguane
- Brand Names
- Azedra
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10IN3
- CAS Number
- 80663-95-2
- Unique Ingredient Identifier
- 35MRW7B4AD
- Background
Synthetic guanethidine derivative that locates phaeochromocytomas and neuroblastomas. The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline. Iodine 123 is a cyclotron-produced radionuclide that decays to Te 123 by electron capture. Images are produced by a I123 MIBG scintigraphy. FDA approved on September 19, 2008.
- Indication
Detection of primary and metastatic pheochromocytoma or neuroblastoma
- Associated Conditions
- Metastatic Adrenal Gland Pheochromocytoma, Metastatic Neuroblastoma, Primary Neuroblastomas, Primary Pheochromocytomas, Unresectable, locally advanced iobenguane-scan positive Paraganglioma, Unresectable, locally advanced iobenguane-scan positive Pheochromocytomas, Unresectable, metastatic iobenguane-scan positive Paraganglioma, Unresectable, metastatic iobenguane-scan positive Pheochromocytomas
- Associated Therapies
- -
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- David Bushnell
- Registration Number
- NCT04614766
- Locations
- 🇺🇸
Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
MIBG Therapy for Patients With MIBG Avid Tumors
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Nationwide Children's Hospital
- Target Recruit Count
- 65
- Registration Number
- NCT02378428
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath